EGFR and lung carcinoma: For instance, epidermal growth factor receptor (EGFR)-mutant lung cancer cells can acquire resistance to EGFR-TKIs, such as gefitinib, via HGF/MET-mediated activation of MAPK/extracellular signal-regulated kinase (ERK)1/2 and PI3K/AKT signaling6.